James Vollins - 27 Jan 2022 Form 4 Insider Report for BIODELIVERY SCIENCES INTERNATIONAL INC

Role
General Counsel, Chief Compliance Officer & Corporate Secretary
Signature
/s/ James Vollins
Issuer symbol
N/A
Transactions as of
27 Jan 2022
Net transactions value
$0
Form type
4
Filing time
31 Jan 2022, 16:57:40 UTC
Previous filing
19 Jan 2022
Next filing
08 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDSI Common Stock Options Exercise $0 +16,276 $0.000000 16,276 27 Jan 2022 Direct
transaction BDSI Common Stock Options Exercise $0 +8,303 +51% $0.000000 24,579 31 Jan 2022 Direct
transaction BDSI Common Stock Options Exercise $0 +3,834 +16% $0.000000 28,413 31 Jan 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSI Stock Options (right to buy) Award $0 +282,055 $0.000000 282,055 27 Jan 2022 Common Stock 282,055 $3.66 Direct F1, F2
transaction BDSI Restricted Stock Units Award $0 +50,546 $0.000000 50,546 27 Jan 2022 Common Stock 50,546 $0.000000 Direct F3, F4
transaction BDSI Restricted Stock Units Options Exercise $0 -16,276 -33% $0.000000 32,552 27 Jan 2022 Common Stock 16,276 $0.000000 Direct F5
transaction BDSI Restricted Stock Units Options Exercise $0 -8,303 -50% $0.000000 8,303 29 Jan 2022 Common Stock 8,303 $0.000000 Direct F6
transaction BDSI Restricted Stock Units Options Exercise $0 -3,834 -100% $0.000000* 0 31 Jan 2022 Common Stock 3,834 $0.000000 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on January 27, 2022.
F2 The stock options were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Issuer's 2019 Stock Option Incentive Plan (the "Plan"). The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
F3 The Restricted Stock Units ("RSUs") were issued to the Reporting Person on January 27, 2022, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest in equal portions on: (i) January 27, 2023; (ii) January 27, 2024; and (iii) January 27, 2025.
F4 Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.
F5 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 27, 2021, under the Plan. The remaining RSUs vest in equal portions on: (i) January 27, 2023; and (ii) January 27, 2024.
F6 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 29, 2020, under the Issuer's 2019 Plan. The remaining RSUs vest on January 29, 2023.
F7 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on January 31, 2019, under the Issuer's 2011 Equity Incentive Plan, as amended.

Remarks:

General Counsel, Chief Compliance Officer & Corporate Secretary